Cellfina has the longest FDA-clearance for a cellulite treatment, proven to treat cellulite’s structural causes in just one treatment.
The Cellfina™ System is intended for long-term improvement in the appearance of cellulite in the buttocks and thigh areas of adult females. Safety and effectiveness in other anatomical areas have not been established. The most common side effects reported were soreness, tenderness, and bruising. The Cellfina™ System is only available through a licensed physician. For full product and safety information, visit cellfina.com/IFU.”
Frequently Asked Questions
Q: What is the Cellfina™ System?
A: Cellfina is the only FDA-cleared minimally invasive, one-time procedure clinically proven to improve the appearance of cellulite for at least two years—the longest FDA-cleared duration for a cellulite treatment. A straightforward solution to cellulite, Cellfina, combines a proven approach with innovative, proprietary technology to produce precise, long-lasting results.
Q: How does the Cellfina™ System work?
A: The Cellfina™ System treats the primary structural cause of cellulite—the connective bands woven throughout fat in the thighs and buttocks. These tight bands pull down the skin, creating the puckering you see on the surface of the skin. Similar to a rubber band under tension, once released, the treated skin bounces back to smooth itself out.
Q: How soon will I see improvements?
A: Results can be seen in as little as three days. In the pivotal study, patient satisfaction was 85 percent at three months, 94 percent at one year and 96 percent at two years, surpassing the patient satisfaction rates of other leading cellulite treatments.*
Q: How long do results last?
A: Patients in the pivotal study showed significant improvement shortly after the treatment, with results lasting at least two years—the longest FDA clearance for a cellulite treatment.
Q: Are there any side effects?
A: No serious adverse events were associated with Cellfina in the pivotal study. The most common side effects reported by patients in the FDA‑cleared pivotal study were soreness, tenderness and bruising. Just three days after treatment, patients rated their pain as minimal (2.7 on a scale of 0 to 10; 0=no pain, 10=extreme pain) and most (82 percent) felt pain only with touch or pressure to the area treated. This minimal pain improved quickly with time. More than 90 percent of patients had no bruising at four weeks.